Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 1

1(20.0%)

5Total

Phase 3(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04829344Phase 3Completed

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Role: lead

NCT05501860Phase 3Completed

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

Role: lead

NCT05325853Phase 3Completed

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

Role: lead

NCT04513652Phase 3Completed

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Role: lead

NCT04759339Phase 1Completed

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

Role: lead

All 5 trials loaded